| Marie Louise Beech, PSYD | |
|
5655 Schooner Loop, Discovery Bay, CA 94505-9213 | |
| (562) 331-0978 | |
| (925) 384-2372 |
| Full Name | Marie Louise Beech |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 30 Years |
| Location | 5655 Schooner Loop, Discovery Bay, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316016793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 18338 (California) | Primary |
| Entity Name | Spiritual Psychologist Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669906657 PECOS PAC ID: 0941573604 Enrollment ID: O20170831003082 |
News Archive
People with type 1 or type 2 diabetes are at higher risk of contracting respiratory, urinary tract and skin infections than people without diabetes, according to an article in the August 1 issue of Clinical Infectious Diseases, now available online.
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis-;deposits of cholesterol, fats and other substances that create plaque, clog arteries and promote heart attacks and stroke. The findings could lead to improved therapies for atherosclerosis, a leading cause of death worldwide.
Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients-with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Canadian Blood Services has reviewed the KPMG report entitled "Independent Review of New Brunswick Blood Options", commissioned by the Government of New Brunswick and the New Brunswick Medical Society.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marie Louise Beech, PSYD Po Box 1873, Discovery Bay, CA 94505-7873 Ph: (562) 331-0978 | Marie Louise Beech, PSYD 5655 Schooner Loop, Discovery Bay, CA 94505-9213 Ph: (562) 331-0978 |
News Archive
People with type 1 or type 2 diabetes are at higher risk of contracting respiratory, urinary tract and skin infections than people without diabetes, according to an article in the August 1 issue of Clinical Infectious Diseases, now available online.
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis-;deposits of cholesterol, fats and other substances that create plaque, clog arteries and promote heart attacks and stroke. The findings could lead to improved therapies for atherosclerosis, a leading cause of death worldwide.
Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients-with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Canadian Blood Services has reviewed the KPMG report entitled "Independent Review of New Brunswick Blood Options", commissioned by the Government of New Brunswick and the New Brunswick Medical Society.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the website of the U.S. Food and Drug Administration (FDA) indicates that an Abbreviated New Drug Application (ANDA) for a generic version of Silenor® (doxepin) 3 mg and 6 mg was submitted on September 16, 2010.
› Verified 1 days ago